Mind Medicine (MindMed) Inc. has announced the publication of results from a Phase 2b clinical study in the Journal of the American Medical Association (JAMA). The study evaluated MM120 (lysergide D-tartrate, LSD) in 198 adults with moderate-to-severe generalized anxiety disorder (GAD). This randomized, placebo-controlled trial assessed four dose levels of MM120 as a monotherapy. The study achieved its primary and key secondary endpoints, demonstrating a dose-response relationship and significant symptom improvement versus placebo on the Hamilton Anxiety Rating Scale (HAM-A). Notably, a 100 µg dose of MM120 showed optimal clinical activity, achieving a greater reduction in HAM-A scores compared to placebo at Week 4, with sustained effects to Week 12. The U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to MM120 for GAD. MindMed is currently enrolling participants in three Phase 3 trials to further evaluate MM120's potential in treating GAD and major depressive disorder (MDD).